Skip to main content


Featured Article
Reyvow (lasmiditan), a first-of-its-kind acute migraine treatment from Eli Lilly, was recently priced and will be available at pharmacies this week.
Shift workers are at a higher risk of reporting headache and are more likely to be diagnosed with migraine than day workers, according to new research.


From a managed care and budget perspective, I think the release and pricing of Aimovig sets a positive stage for this class of medications.
The burden of headache disorders is compounded by delayed diagnosis and other barriers to effective therapy.
Back to Top